Carpagnano GE, Resta E, Povero M, et al.

Title: Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.

Citation: Sci Rep
2021;11:5453.

Country: Italy | Indication: Asthma

This is an independent study

http://tago.ca/33750842
Scan to access the publication or visit
http://tago.ca/33750842